Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Alkermes' Vivitrol Live Up To Commercial Potential In Opioid Dependence?

This article was originally published in The Pink Sheet Daily

Executive Summary

Company does not plan to compete against market-leading Suboxone, and will initially target the newly addicted, such as young adults, and certain professionals who can't take available treatments.
Advertisement

Related Content

Titan Hopes To Tap Into Niche Drug Addiction Market With Six-Month Implant
Titan Hopes To Tap Into Niche Drug Addiction Market With Six-Month Implant
Alkermes Needs To Eject DVD Of Vivitrol Patient Testimonials, FDA Says
Alkermes Needs To Eject DVD Of Vivitrol Patient Testimonials, FDA Says
Vivitrol's Opioid Abuse Claim Will Likely Need Monitoring and Support Services
Vivitrol's Opioid Abuse Claim Will Likely Need Monitoring and Support Services
Reckitt Benckiser Gets FDA OK For Film Formulation Of Top-Selling Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS071300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel